A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.
复制标题
DOI:
10.1038/clpt.2009.291
复制
发表时间:
2010-04
影响因子:
6.7
通讯作者:
中科院分区:
文献类型:
--
作者:
Warfarin demonstrates wide interindividual variability that is partly mediated by variants in CYP2C9 and VKORC1. Whether variants in CALU (vitamin K reductase regulator) influence warfarin dose is unknown. We resequenced CALU regions in a discovery cohort of dose-outliers: patients with high(>90th percentile, n=55) or low(<10th percentile, n=53) dose requirements(after accounting for known genetic and nongenetic variables). One CALU variant, rs339097, was associated with high-doses(p=0.01). We validated this variant as a predictor of higher warfarin doses in two replication cohorts: 1)496 patients of mixed ethnicity, 2)194 African-American patients. The G allele of rs339097(African-American and Caucasian allele frequency 0.14 and 0.002, respectively), was associated with a 14.5%(SD±7%) greater therapeutic dose(p=0.03) in the first replication cohort and a higher than predicted dose in the second replication cohort(allele frequency=0.14, one-sided p=0.03). CALU rs339097 A>G is associated with higher warfarin dose requirements independent of known genetic and nongenetic predictors of warfarin dose in African-Americans.
登录
查看更多内容
影响因子:
64.8
作者:
Rost, S;Fregin, A;Oldenburg, J
通讯作者:
Oldenburg, J
影响因子:
7.5
作者:
Odén, A;Fahlén, M;Hart, RG
通讯作者:
Hart, RG
影响因子:
30.8
作者:
Arking, Dan E.;Pfeufer, Arne;Chakravarti, Aravinda
通讯作者:
Chakravarti, Aravinda
DOI:
10.1111/j.2517-6161.1995.tb02031.x
发表时间:
1995-01-01
影响因子:
5.8
作者:
BENJAMINI, Y;HOCHBERG, Y
通讯作者:
HOCHBERG, Y
影响因子:
158.5
作者:
Ridker, PM;Goldhaber, SZ;Boross-Harmer, S
通讯作者:
Boross-Harmer, S